Factors associated with treatment failure of Helicobacter pylori infection in a developing country

Journal of Clinical Gastroenterology

Volumn 35, Issue 4, 2002, Pages 315-320

  Queiroz, Dulciene Maria Magalhães ^a   Dani, Renato ^b   Silva, Luciana Diniz ^a   Santos, Adriana ^a   Moreira, Liano Sia ^b   Rocha, Gifone Aguiar ^a   Corrêa, Paulo Renato Valle ^a   Reis, Luiz Fernando Abrahão ^b   Nogueira, Ana Margarida Ferreira ^a   Álvares Cabral, Mônica Maria Demas ^a   Esteves, Ana Maria Brás ^a   Tanure, Jansen ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Governador Israel Pinheiro   (Brazil)

Author keywords

CagA; Clarithromycin; Furazolidone; H. pylori treatment failure; Helicobacter pylori

Indexed keywords

CAGA PROTEIN; CLARITHROMYCIN; FURAZOLIDONE; PANTOPRAZOLE; RNA 23S;

ADOLESCENT; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; FEMALE; GASTRITIS; GENDER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TREATMENT FAILURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DEVELOPING COUNTRIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; RISK FACTORS; SEX FACTORS; SULFOXIDES; TREATMENT FAILURE;

EID: 0036785427     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200210000-00007     Document Type: Article

References (26)

1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10:720-41.
2. Wilhelmensen I. Quality of life and Helicobacter pylori eradication. Scand J Gastroenterol 1996;31(Suppl 221):18-20.
3. Morgner A, Thiede C, Bayerdorffer E. et al. Long-term follow-up of gastric MALT lymphoma after H. pylori eradication. Curr Gastroenterol Rep 2001;3: 512-22.
4. Mégraud F. Rationale for the choice of antibiotics for eradication of Helicobacter pylori. Eur J Gastroenterol 1995;7:49-54.
5. Preston JG. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Ther 1996;10:469-86.
6. Dani R, Queiroz DMM, Dias MGM, et al. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther 1999;13:1647-52.
7. Nakajima S, Graham DY, Hattori T, et al. Strategy for treatment of Helicobacter pylori infection in adults: II Practical policy. Curr Pharm Des 2000;6:1515-29.
8. Tytgat GA. Treatment of peptic ulcer. Digestion 1998;59:446-52.
9. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999;57:905-20.
10. van der Hulst RW, Weel JF, Verheul SB, et al. Treatment of Helicobacter pylori infection with low and high dose omeprazole combined with amoxicillin and the effect of early retreatment: a prospective randomised double blind study. Aliment Pharmacol Ther 1996;10:165-71.
11. Crabtree JE, Covacci A, Farmery SM, et al. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with cagA-positive phenotype. J Clin Pathol 1995;48:41-5.
12. van Doorn LJ, Schneeberger PM, Nouhan N, et al. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46:321-6.
13. Broutet N, Marais A, Lamouliatte H, et al. CagA status and eradication treatment outcome of anti- Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 2001;39:1319-22.
14. Dixon MF, Genta RM, Yardley JH. et al. Classification in grading of gastritis: the update Sydney system. Am J Surg Pathol 1996;20:1161-81.
15. Queiroz DMM, Mendes EN, Rocha GA. Indicator medium for isolation of Campylobacter pylori. J Clin Microbiol 1987;25:2378-79.
16. Fox JG, Dewhirst FE, Fraser GJ, et al, Intra-cellular Campylobacter-like organism from ferrets and hamsters with proliferative bowel disease in a Desulfovibrio sp. J Clin Microbiol 1994;32:1229-37.
17. Kelly SM, Pitcher MC, Farmery SM, et al. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107:1671-4.
18. Peek RM Jr, Miller GG, Tham KT, et al. detection of Helicobacter pylori gene expression in human gastric mucosa. J Clin Microbiol 1995;33:28-32.
19. Meier A. Kirschner P, Springer B. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994;38:381-84.
20. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in H. pylori. Antimicrob Agents Chemother 1996; 40:477-80.
21. Hosmer DW, Lemeshow S. Applied logistic regression. New York: JH Wiley Interscience Publication, 2000.
22. Goodwin CS, Blake P, Blincow G. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 1986;17:309-14.
23. Queiroz DMM, Campos DV, Magalhães PP, et al. Comparison of agar dilution method and E-test for metronidazole and clarithromycin resistance evaluation in Helicobacter pylori strains in Helicobacter [abstract]. Basic Mechanisms to Clinical Care 1998;A26.
24. Van Zwet AA, Thijs JC, Van der Wouden EJ, et al. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther 1997;11:533-5.
25. Dette GA, Knothe H. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leucocytes. J Antimicrob Chemother 1986; 18:73-82.
26. Cover TL, Glupzynski Y, Lage AP, et al. Serologic detection of infection with cagA Helicobacter pylori strains. J Clin Microbiol 1995;33:1496-500.